Catalog No.
DHC22403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CCP, PDN-21, CALCA, Calcitonin carboxyl-terminal peptide, Calcitonin, CALC1, Calcitonin gene-related peptide II, CALCB, Calcitonin gene-related peptide 2, Beta-CGRP, CALC2, CGRP-II, Beta-type CGRP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01258 & P10092
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ALD-403, CAS: 1644539-04-7
Clone ID
Eptinezumab
Eptinezumab: First Approval, PMID: 32266704
Eptinezumab for the treatment of migraine, PMID: 31840684
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2, PMID: 32209650
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1), PMID: 32075406
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial, PMID: 31234642
Eptinezumab, PMID: 32697467
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study, PMID: 33023473
Eptinezumab for the preventive treatment of migraine, PMID: 33280422
Eptinezumab (Vyepti) for migraine prevention, PMID: 32555116
Migraine overview and summary of current and emerging treatment options, PMID: 30681821
Antibodies to watch in 2020, PMID: 31847708
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing, PMID: 33165938
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study, PMID: 33250209
Eptinezumab, PMID: 34292696
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine, PMID: 32155317
Monoclonal antibodies for the prevention of migraine, PMID: 31550937
CGRP as the target of new migraine therapies - successful translation from bench to clinic, PMID: 29691490
What's New in the Treatment of Migraine?, PMID: 31393282
Role of CGRP in Migraine, PMID: 30725283
Drugs for Migraine, PMID: 33434187
Antibodies to watch in 2019, PMID: 30516432
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies, PMID: 33287305
Eptinezumab for the treatment of migraine, PMID: 34009094
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans, PMID: 32173558
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2, PMID: 33314079
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment, PMID: 30242830
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention, PMID: 32758365
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention, PMID: 30651064
Recent Advances in Pharmacotherapy for Episodic Migraine, PMID: 31556018
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review, PMID: 31291020
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials, PMID: 33781209
Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis, PMID: 32460120
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial, PMID: 34128999
Immunogenicity of biologic therapies for migraine: a review of current evidence, PMID: 33413094
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients, PMID: 33855218
Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials, PMID: 33676408
Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants, PMID: 33008505
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class, PMID: 31020659
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome, PMID: 34013992
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data, PMID: 29110503
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial, PMID: 33740902
Intravenous Migraine Treatment in Children and Adolescents, PMID: 32638172
[Novel migraine treatment with CGRP-related monoclonal antibodies], PMID: 32893246
Rimegepant (Nurtec ODT) for acute treatment of migraine, PMID: 32555113
CGRP, Amylin, Immunology, and Headache Medicine, PMID: 30390312
Antigens and Antibodies in Disease With Specifics About CGRP Immunology, PMID: 30187471
CGRP antagonists for decreasing migraine frequency: New options, long overdue, PMID: 32238376
Monoclonal Antibodies to Prevent Migraine Headaches, PMID: 30855775
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives, PMID: 32434430
Calcitonin-gene-related peptide pathway mAbs and migraine prevention, PMID: 29432219
For research use only. Not for human or drug use.
